{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:31:30Z","timestamp":1787970690312,"version":"build-2784847793"},"reference-count":41,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008108","name":"Taipei Tzu-Chi Hospital","doi-asserted-by":"publisher","award":["TCRD-TPE-111-10"],"award-info":[{"award-number":["TCRD-TPE-111-10"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer is the most lethal gynecologic malignancy in the United States. Some patients affected by ovarian cancers often present genome instability with one or more of the defects in DNA repair pathways, particularly in homologous recombination (HR), which is strictly linked to mutations in breast cancer susceptibility gene 1 (BRCA 1) or breast cancer susceptibility gene 2 (BRCA 2). The treatment of ovarian cancer remains a challenge, and the majority of patients with advanced-stage ovarian cancers experience relapse and require additional treatment despite initial therapy, including optimal cytoreductive surgery (CRS) and platinum-based chemotherapy. Targeted therapy at DNA repair genes has become a unique strategy to combat homologous recombination-deficient (HRD) cancers in recent years. Poly (ADP-ribose) polymerase (PARP), a family of proteins, plays an important role in DNA damage repair, genome stability, and apoptosis of cancer cells, especially in HRD cancers. PARP inhibitors (PARPi) have been reported to be highly effective and low-toxicity drugs that will tremendously benefit patients with HRD (i.e., BRCA 1\/2 mutated) epithelial ovarian cancer (EOC) by blocking the DNA repair pathways and inducing apoptosis of cancer cells. PARP inhibitors compete with NAD+ at the catalytic domain (CAT) of PARP to block PARP catalytic activity and the formation of PAR polymers. These effects compromise the cellular ability to overcome DNA SSB damage. The process of HR, an essential error-free pathway to repair DNA DSBs during cell replication, will be blocked in the condition of BRCA 1\/2 mutations. The PARP-associated HR pathway can also be partially interrupted by using PARP inhibitors. Grossly, PARP inhibitors have demonstrated some therapeutic benefits in many randomized phase II and III trials when combined with the standard CRS for advanced EOCs. However, similar to other chemotherapy agents, PARP inhibitors have different clinical indications and toxicity profiles and also face drug resistance, which has become a major challenge. In high-grade epithelial ovarian cancers, the cancer cells under hypoxia- or drug-induced stress have the capacity to become polyploidy giant cancer cells (PGCCs), which can survive the attack of chemotherapeutic agents and start endoreplication. These stem-like, self-renewing PGCCs generate mutations to alter the expression\/function of kinases, p53, and stem cell markers, and diploid daughter cells can exhibit drug resistance and facilitate tumor growth and metastasis. In this review, we discuss the underlying molecular mechanisms of PARP inhibitors and the results from the clinical studies that investigated the effects of the FDA-approved PARP inhibitors olaparib, rucaparib, and niraparib. We also review the current research progress on PARP inhibitors, their safety, and their combined usage with antiangiogenic agents. Nevertheless, many unknown aspects of PARP inhibitors, including detailed mechanisms of actions, along with the effectiveness and safety of the treatment of EOCs, warrant further investigation.<\/jats:p>","DOI":"10.3390\/ijms23158125","type":"journal-article","created":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T22:49:02Z","timestamp":1658702942000},"page":"8125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review"],"prefix":"10.3390","volume":"23","author":[{"given":"Chien-Hui","family":"Lau","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kok-Min","family":"Seow","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Yang-Ming Chiao-Tung University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4758-0351","authenticated-orcid":false,"given":"Kuo-Hu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan"},{"name":"School of Medicine, Tzu-Chi University, Hualien 970, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer Statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"x111","DOI":"10.1093\/annonc\/mds300","article-title":"New Insights into Ovarian Cancer Pathology","volume":"23","author":"Prat","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent Progress in The Diagnosis and Treatment of Ovarian Cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2017.04.006","article-title":"PARP Inhibitors Alone and In Combination with Other Biological Agents in Homologous Recombination Deficient Epithelial Ovarian Cancer","volume":"114","author":"Gadducci","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/cas.13530","article-title":"Crosstalk of DNA Double-Strand Break Repair Pathways in Poly(ADP-ribose) Polymerase Inhibitor Treatment of Breast Cancer Susceptibility Gene 1\/2-Mutated Cancer","volume":"109","author":"Shigeaki","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gore.2019.07.007","article-title":"BRCA Mutation in High Grade Epithelial Ovarian Cancers","volume":"29","author":"Manchana","year":"2019","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_7","first-page":"215","article-title":"PARP inhibitors: Review of Mechanisms of Action and BRCA1\/2 Mutation Targeting","volume":"15","author":"Dziadkowiec","year":"2016","journal-title":"Prz. Menopauzalny"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA Damage, Repair and Mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP Inhibitors: Synthetic Lethality in The Clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/GCO.0000000000000517","article-title":"Poly-ADP-Ribosyl-Polymerase Inhibitor Resistance Mechanisms and Their Therapeutic Implications","volume":"31","author":"Kelly","year":"2019","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/GCO.0000000000000600","article-title":"Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer","volume":"32","author":"Kubalanza","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109661","DOI":"10.1016\/j.biopha.2019.109661","article-title":"Mechanism and Current Progress of Poly ADP-Ribose Polymerase (PARP) Inhibitors in The Treatment of Ovarian Cancer","volume":"123","author":"Zheng","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/ol.2020.11951","article-title":"PARP Inhibitors and Epithelial Ovarian Cancer: Molecular Mechanisms, Clinical Development and Future Prospective (Review)","volume":"20","author":"Loizzi","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"629266","DOI":"10.3389\/fphar.2020.629266","article-title":"DNA Repair Pathways in Cancer Therapy and Resistance","volume":"11","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ygyno.2015.02.017","article-title":"Two Decades Beyond BRCA1\/2: Homologous Recombination, Hereditary Cancer Risk and A Target for Ovarian Cancer Therapy","volume":"137","author":"Walsh","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib Monotherapy in Patients with Advanced Cancer and A Germline BRCA1\/2 Mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and Safety of Olaparib Monotherapy in Germline BRCA1\/2 Mutation Carriers with Advanced Ovarian Cancer and Three or More Lines of Prior Therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in A Randomised Phase 2 Trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and A BRCA1\/2 Mutation (SOLO2\/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"18","author":"Ledermann","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and A BRCA1\/2 Mutation (SOLO2\/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"27","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer and A BRCA Mutation (SOLO1\/GOG 3004): 5-Year Follow-Up of A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A Phase I-II Study of The Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1\/2-Mutated Ovarian Carcinoma or Other Solid Tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in Relapsed, Platinum-Sensitive High-Grade Ovarian Carcinoma (ARIEL2 Part 1): An International, Multicentre, Open-Label, Phase 2 Trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor Activity and Safety of The PARP Inhibitor Rucaparib in Patients with High-Grade Ovarian Carcinoma and A Germline or Somatic BRCA1 or BRCA2 Mutation: Integrated Analysis of Data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma After Response to Platinum Therapy (ARIEL3): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus Standard-Of-Care Chemotherapy in Patients with Relapsed Ovarian Cancer and A Deleterious BRCA1 or BRCA2 Mutation (ARIEL4): An International, Open-Label, Randomized, Phase 3 Trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-Angiogenic Agents in Ovarian Cancer: Past, Present, and Future","volume":"27","author":"Monk","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sopo, M., Anttila, M., H\u00e4m\u00e4l\u00e4inen, K., Kivel\u00e4, A., Yl\u00e4-Herttuala, S., Kosma, V.-M., Keski-Nisula, L., and Sallinen, H. (2019). Expression Profiles of VEGF-A, VEGF-D and VEGFR1 Are Higher in Distant Metastases Than in Matched Primary High Grade Epithelial Ovarian Cancer. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5757-3"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-Induced Down-Regulation of BRCA1 Expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/1535-7163.MCT-10-0976","article-title":"Assessing the Activity of Cediranib, A VEGFR-2\/3 Tyrosine Kinase Inhibitor, Against VEGFR-1 and Members of The Structurally Related PDGFR Family","volume":"10","author":"Brave","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in The Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2018.01.011","article-title":"The Poly (ADP Ribose) Polymerase Inhibitor Niraparib: Management of Toxicities","volume":"149","author":"Moore","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and Dose Modification for Patients Receiving Niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/biolre\/ioab102","article-title":"Polyploid giant cancer cells and ovarian cancer: New insights into mitotic regulators and polyploidy","volume":"105","author":"Richards","year":"2021","journal-title":"Biol. Reprod."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:55:26Z","timestamp":1760140526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":41,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23158125"],"URL":"https:\/\/doi.org\/10.3390\/ijms23158125","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]}}}